MX2019000744A - Formas solidas del inhibidor de la tirosina treonina cinasa (ttk). - Google Patents
Formas solidas del inhibidor de la tirosina treonina cinasa (ttk).Info
- Publication number
- MX2019000744A MX2019000744A MX2019000744A MX2019000744A MX2019000744A MX 2019000744 A MX2019000744 A MX 2019000744A MX 2019000744 A MX2019000744 A MX 2019000744A MX 2019000744 A MX2019000744 A MX 2019000744A MX 2019000744 A MX2019000744 A MX 2019000744A
- Authority
- MX
- Mexico
- Prior art keywords
- crystal
- tyreosine
- treonina
- cinasa
- ttk
- Prior art date
Links
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 239000013078 crystal Substances 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000005340 bisphosphate group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
- C30B29/58—Macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/02—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/14—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invencion se refiere a un novedoso co-cristal del compuesto de formula (I): (Formula (I)) en donde la molecula co-formadora es hemihidrato de bifosfato, a procesos para la preparacion del co-cristal, a composiciones farmaceuticas que contienen el co-cristal, al uso de tal co-cristal en la manufactura de un medicamento para uso en el tratamiento de cancer y a métodos para tratar tales enfermedades en el cuerpo humano o animal por administracion de una cantidad terapeuticamente efectiva de tal co-cristal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662363424P | 2016-07-18 | 2016-07-18 | |
| PCT/CA2017/050848 WO2018014116A1 (en) | 2016-07-18 | 2017-07-13 | Solid forms of ttk inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019000744A true MX2019000744A (es) | 2019-05-02 |
| MX385289B MX385289B (es) | 2025-03-18 |
Family
ID=60991755
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000744A MX385289B (es) | 2016-07-18 | 2017-07-13 | Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk). |
| MX2021008658A MX2021008658A (es) | 2016-07-18 | 2019-01-17 | Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk). |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008658A MX2021008658A (es) | 2016-07-18 | 2019-01-17 | Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk). |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10584130B2 (es) |
| EP (1) | EP3484888B1 (es) |
| JP (2) | JP6961675B2 (es) |
| KR (2) | KR102537088B1 (es) |
| CN (2) | CN109476667B (es) |
| AU (2) | AU2017299850B2 (es) |
| BR (1) | BR112019000813A2 (es) |
| CA (1) | CA3030230A1 (es) |
| DK (1) | DK3484888T3 (es) |
| ES (1) | ES2945108T3 (es) |
| FI (1) | FI3484888T5 (es) |
| HR (1) | HRP20230481T1 (es) |
| HU (1) | HUE061872T2 (es) |
| IL (1) | IL264173B2 (es) |
| LT (1) | LT3484888T (es) |
| MA (1) | MA45691A (es) |
| MX (2) | MX385289B (es) |
| PL (1) | PL3484888T3 (es) |
| PT (1) | PT3484888T (es) |
| RS (1) | RS64210B1 (es) |
| RU (2) | RU2753905C2 (es) |
| SG (2) | SG10202103332UA (es) |
| SI (1) | SI3484888T1 (es) |
| SM (1) | SMT202300156T1 (es) |
| TW (2) | TWI824313B (es) |
| WO (1) | WO2018014116A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3484888T1 (sl) | 2016-07-18 | 2023-07-31 | University Health Network | Trdne oblike inhibitorja ttk |
| KR20240175121A (ko) | 2023-06-12 | 2024-12-19 | 한국재료연구원 | 희토류 산화물을 이용한 입계확산물질의 제조방법 및 이를 이용한 R-Fe-B계 영구자석의 제조방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101732717A (zh) | 2001-02-21 | 2010-06-16 | 诺华疫苗和诊断公司 | 用于诊断和作为癌症治疗靶标的ttk |
| US7528138B2 (en) * | 2004-11-04 | 2009-05-05 | Vertex Pharmaceuticals Incorporated | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
| TW201107329A (en) * | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| TWI541243B (zh) * | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| US20130303532A1 (en) * | 2010-12-17 | 2013-11-14 | Bayer Intellectual Property Gmbh | Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders |
| JP6377068B2 (ja) | 2012-11-16 | 2018-08-22 | ユニバーシティ・ヘルス・ネットワーク | ピラゾロピリミジン化合物 |
| EA029372B1 (ru) * | 2013-11-15 | 2018-03-30 | Юниверсити Хелс Нетуорк | Пиразолопиримидиновые соединения |
| SI3484888T1 (sl) | 2016-07-18 | 2023-07-31 | University Health Network | Trdne oblike inhibitorja ttk |
-
2017
- 2017-07-13 SI SI201731352T patent/SI3484888T1/sl unknown
- 2017-07-13 MA MA045691A patent/MA45691A/fr unknown
- 2017-07-13 BR BR112019000813-6A patent/BR112019000813A2/pt active Search and Examination
- 2017-07-13 IL IL264173A patent/IL264173B2/en unknown
- 2017-07-13 SG SG10202103332UA patent/SG10202103332UA/en unknown
- 2017-07-13 DK DK17830139.6T patent/DK3484888T3/da active
- 2017-07-13 SG SG11201900113UA patent/SG11201900113UA/en unknown
- 2017-07-13 KR KR1020197001829A patent/KR102537088B1/ko active Active
- 2017-07-13 FI FIEP17830139.6T patent/FI3484888T5/fi active
- 2017-07-13 RU RU2019101109A patent/RU2753905C2/ru active
- 2017-07-13 KR KR1020237017039A patent/KR102700233B1/ko active Active
- 2017-07-13 PT PT178301396T patent/PT3484888T/pt unknown
- 2017-07-13 CN CN201780043473.1A patent/CN109476667B/zh active Active
- 2017-07-13 RS RS20230383A patent/RS64210B1/sr unknown
- 2017-07-13 WO PCT/CA2017/050848 patent/WO2018014116A1/en not_active Ceased
- 2017-07-13 HR HRP20230481TT patent/HRP20230481T1/hr unknown
- 2017-07-13 HU HUE17830139A patent/HUE061872T2/hu unknown
- 2017-07-13 JP JP2019501928A patent/JP6961675B2/ja active Active
- 2017-07-13 RU RU2021124795A patent/RU2021124795A/ru unknown
- 2017-07-13 ES ES17830139T patent/ES2945108T3/es active Active
- 2017-07-13 PL PL17830139.6T patent/PL3484888T3/pl unknown
- 2017-07-13 LT LTEPPCT/CA2017/050848T patent/LT3484888T/lt unknown
- 2017-07-13 CA CA3030230A patent/CA3030230A1/en active Pending
- 2017-07-13 US US16/318,426 patent/US10584130B2/en active Active
- 2017-07-13 AU AU2017299850A patent/AU2017299850B2/en active Active
- 2017-07-13 CN CN202210644487.1A patent/CN115093416B/zh active Active
- 2017-07-13 EP EP17830139.6A patent/EP3484888B1/en active Active
- 2017-07-13 MX MX2019000744A patent/MX385289B/es unknown
- 2017-07-13 SM SM20230156T patent/SMT202300156T1/it unknown
- 2017-07-18 TW TW110137560A patent/TWI824313B/zh active
- 2017-07-18 TW TW106123975A patent/TWI745400B/zh active
-
2019
- 2019-01-17 MX MX2021008658A patent/MX2021008658A/es unknown
-
2020
- 2020-03-02 US US16/806,392 patent/US11104681B2/en active Active
-
2021
- 2021-08-24 AU AU2021221447A patent/AU2021221447B2/en active Active
- 2021-08-27 US US17/459,725 patent/US11878980B2/en active Active
- 2021-10-13 JP JP2021167806A patent/JP7263473B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| NZ777871A (en) | Small molecule modulators of il-17 | |
| NI202000099A (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| CR20220236A (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune | |
| MX2019005009A (es) | 1,2,4-triazolonas 2,4,5-trisustituidas. | |
| MX2019012884A (es) | Terapia de combinacion. | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| DOP2021000198A (es) | Compuestos y su uso en el tratamiento del cáncer | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| PH12018500904A1 (en) | Peptide macrocycles against acinetobacter baumannii | |
| BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
| BR112012009376B8 (pt) | composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica | |
| CO6460769A2 (es) | Inhibidores de la replicación viral novedosos | |
| MX394961B (es) | Composiciones para usarse en el tratamiento de enfermedades relacionadas con la interleucina 6 | |
| BR112015016315A2 (pt) | fluoro-[1,3]oxazinas como inibidores de bace1 | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| BR112015019412A8 (pt) | inibidores de bace1, seus usos, e composição farmacêutica | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| TW201613578A (en) | Pharmaceutical combinations | |
| BR112022010181A2 (pt) | Composto tri-heterocíclico como inibidor de jak e uso do mesmo | |
| MX2019000744A (es) | Formas solidas del inhibidor de la tirosina treonina cinasa (ttk). | |
| BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação | |
| BR112023024085A2 (pt) | Composto usado como inibidor de bcr-abl |